NDAORALTABLETPriority Review
Approved
Aug 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
HYDROCORTONE (hydrocortisone) by Merck & Co. is corticosteroid hormone receptor agonists [moa]. Approved for the following conditions, rheumatoid arthritis, rheumatoid arthritis and 8 more indications. First approved in 1952.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROCORTONE (hydrocortisone) is an oral corticosteroid tablet approved in 1952 that acts as a glucocorticoid hormone receptor agonist. It is used to treat inflammatory and autoimmune conditions including rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, ulcerative colitis, and select hematologic malignancies. Hydrocortisone works by suppressing immune responses and reducing inflammation across multiple organ systems.
LOE Approaching
As LOE approaches, the HYDROCORTONE brand team faces declining market exclusivity and likely consolidation, signaling potential workforce realignment and focus shift to generic transition support.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications (9)
Worked on HYDROCORTONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.